Royalty Report: Drugs, Disease, Therapeutic – Collection: 243432

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243432

License Grant
Licensor grants an exclusive license or sublicense even as to Licensor, with the right to grant sublicenses pursuant to Licensor Patent Rights and Know-How to research, develop, make, have made, use, sell, offer to sell, supply, cause to be supplied, import and have imported Licensed Product in the Field in the Territory.

With the Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information, Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license, with the right to sublicense to Licensee Affiliates, to use only for research purposes any and all Licensor Know-How or Confidential Information of Licensor disclosed to Licensee during the Term but not any Licensor Patent Rights, it being understood and agreed that neither Licensee nor any of its Affiliates will have any right or license to use any such Licensor Know-How or Licensor Confidential Information with respect to Compound or Licensed Product after termination of this Agreement and/or in connection with obtaining Regulatory Approval of a pharmaceutical product and/or the sale or manufacture for sale of any pharmaceutical product.

License Property
Compound means Licensors-1070 and all modifications, enhancements, improvements and backups which result in a heterobifunctional, pan selectin antagonist comprised of a selectin antagonist linked to a benzy amino sulfuric acid (BASA)  and mimicking the native glycosulfopeptide ligand for E and P – selectins and all isomers, tautomers, enantlomers, hydrates, esters, racemates, polymorphs, metabolites, prodrugs and salts of any of the compounds that are a heterobifunctional, pan selectin antagonist comprised of a selectin antagonist linked to a benzy amino sulfuric acid (BASA)  and mimicking the native glycosulfopeptide ligand for E and P – selectins.

1070 is a rationally designed glycomimetic inhibitor of E-, P- and L-selectins that interferes in a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.

Field of Use
1070 is initially being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.

IPSCIO Record ID: 286027

License Grant
Licensor hereby grants to Koran Licensee a sole and exclusive right and license in the Territory to use and sell any of the Products for the indications as specified herein.
License Property
Product means (a) TBC-11251, the lead candidate for Licensors Endothelin Receptor Antagonist (TBC-11251 is more particularly described hereto), and/or (b) TBC-1269, the lead candidate for Licensors Selectin Antagonist (TBC-1269 is more particularly described hereto).

TBC11251 is a sulfonamide based antagonist of endothelin binding to its receptors. The compound exhibits selectivity for binding to the A subtype of the endothelin receptors relative to the B subtype. The chemical structure of TBC11251 is 4-chloro-3-methyl-5-(2-(2-(6-methylbenzo[d][1.3]dioxol-5-yl)acetyl)-3-thienylsulfonamido)isoxazole (it is also referred to by N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4,5- (methylenedioxy)phenylacetyl]thiophene-3-sulfphonamide). The compound is also referred to as various salt forms which include, but are not limited to, the sodium phosphate salt (TBC11251Z) and the sodium salt (TBC11251Na).

Application 1 PCT/US94/05755 'Sulfonamides and derivatives thereof that modulate the activity of endothelin' filed April 4, 1994.

Application 2 PCT/US96/04759 'Thienyl-, furyl, pyrrolyl-, and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin' filed April 4, 1996.

TBC1269 is a mannosylated biphenyl based selectin antagonist which is capable of blocking the binding of E-,P-, and L- selectin to their respective ligands. The compound is also referred to as various sale forms which include, but are not limited to, the sodium salt (TBC1269Na).

Patents covering TBC1269 in the Territories
Application PCT/US96/11032 entitled 'Binding of E-selecting, P-selectin or L-selectin to Sialyl-Lewis or Sialyl-Lewis' filed June 26, 1996.
Application 08/655 entitled 'High yield stereospecific mannosylation' filed May 20, 1996.

Endothelin Receptor Antagonist means a molecular compound under development by Licensor which inhibits the binding of endothelin to a distinct cell surface receptor.

Novastan(R) means a non-protein, synthetic small molecule thrombin inhibitor developed by Licensor that directly and selectively binds to and inactivates thrombin in the blood plasma.

Selectin Antagonist means a molecular compound under development by Licensor which inhibits the selectin-mediated adhesion of inflamed endothelium to the surface of white blood cells.

Endothelin receptors are G protein-coupled receptors whose activation result in elevation of intracellular-free calcium,[2] which constricts the smooth muscles of the blood vessels, raising blood pressure, or relaxes the smooth muscles of the blood vessels, lowering blood pressure, among other functions.

Field of Use
This agreement pertains to the drug industry relating to indications of congestive heart failure , chronic obstructive pulmonary disease, primary pulmonary hypertension, asthma and psoriasis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.